ProQR Therapeutics (PRQR) FCF Margin (2013 - 2026)
ProQR Therapeutics (PRQR) posted FCF Margin of 572.01% for Q1 2026, down 60.89% sequentially from 355.52% in Q4 2025, and down 20467.0% YoY from N/an in Q1 2025.
ProQR Therapeutics (PRQR) FCF Margin (2013 - 2026) Analysis & Trends
ProQR Therapeutics has reported FCF Margin for 14 years, with the latest figure at 572.01% in Q1 2026.
- Quarterly FCF Margin fell 20467.0% year-over-year to 572.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 391.32% (down 16157.0% YoY) and the FY2025 annual result came in at 349.6%, down 13543.0% from the prior year.
- FCF Margin eased to 572.01% in Q1 2026 per PRQR's latest filing, from 355.52% in the prior quarter.
- Over five years, FCF Margin peaked at 6821.53% in Q1 2023 and troughed at 2675.28% in Q4 2022.
- A 5-year average of 336.23% and a median of 367.34% in 2025 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2024: FCF Margin surged 865436 bps in 2023, then plunged 714512 bps in 2024.
- Over 5 years, FCF Margin stood at 2675.28% in 2022, then jumped by 93 bps to 173.93% in 2023, then plunged by 97 bps to 341.98% in 2024, then decreased by 4 bps to 355.52% in 2025, then plunged by 61 bps to 572.01% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 572.01%, 355.52%, and 418.67% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | -572.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -572.01% |
| Dec 31, 2025 | -355.52% |
| Sep 30, 2025 | -418.67% |
| Jun 30, 2025 | -315.67% |
| Mar 31, 2025 | -367.34% |
| Dec 31, 2024 | -341.98% |
| Sep 30, 2024 | -139.76% |
| Jun 30, 2024 | -113.28% |
| Mar 31, 2024 | -323.60% |
| Dec 31, 2023 | -173.93% |
| Sep 30, 2023 | -587.88% |
| Jun 30, 2023 | -891.12% |
| Mar 31, 2023 | 6,821.53% |
| Dec 31, 2022 | -2,675.28% |
| Sep 30, 2022 | -1,857.25% |
| Jun 30, 2022 | -1,571.29% |
| Mar 31, 2022 | -1,832.83% |
| Dec 31, 2021 | 1,910.88% |
| Sep 30, 2021 | -903.90% |
| Jun 30, 2021 | -4,085.19% |